Hemanext ONE is the first meaningful FDA-authorized processing and storage technology proven to mitigate the red blood cell (RBC) storage lesion.1-4
Transforming Red Blood Cells 
Advancing Care.TM
Hemanext is a global biomedical technology pioneer in transfusion medicine. We recognize the vital role of blood for patients and are committed to optimizing its therapeutic impact and value to the healthcare system. Focused on the study of hypoxically stored RBCs, our research and development efforts aim to significantly improve the quality of stored RBCs worldwide. We strive to achieve our mission of delivering innovations that improve the standard of care for patients who rely on transfusions by transforming RBCs through protecting their quality, functionality, and viability during storage.
Latest News and Events
Hemanext Inc. Awarded $2.9M NIH Grant to Advance Clinical Initiatives in the United States
LEXINGTON, Mass., October 14th, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, has been awarded a three-year Small Business Innovation Research Grant (SBIR) Phase II for a project titled, “Efficacy of...
New Chief Commercial Officer Joins Hemanext Team to Drive Execution
LEXINGTON, Mass., September 24th, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, is pleased to welcome Mr. Shane Ray to the team as Chief Commercial Officer (CCO). In this role, Shane will lead the...
Co-Investigator of Clinical Safety Study Presents at EHA
LEXINGTON, Mass., August 19, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces that the data from its safety study was accepted in the form of an oral presentation at the European Hematology...
Hemanext Announces Close of Series B-3 Equity Financing Round
LEXINGTON, Mass., July 22, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage and transfusion technology, announced the close of its Series B-3 equity financing round. The round raised $18.9 million at a post-money valuation of $172...
Hemanext Welcomes New Member to Board of Directors
LEXINGTON, Mass., May 21, 2025, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector,...
Hemanext Research
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.